Sogroya is a long-acting form of somatropin. Somatropin is also called human growth hormone. Sogroya is made by attaching human growth hormone to a small protein that helps it stay in the body longer ...
Sogroya is administered by subcutaneous injection once weekly. The Food and Drug Administration (FDA) has approved Sogroya ® (somapacitan-beco) for the treatment of pediatric patients aged 2.5 years ...
Sogroya is administered by subcutaneous injection one time each week. The Food and Drug Administration (FDA) has approved Sogroya® (somapacitan-beco; Novo Nordisk) injection for the replacement of ...
Sogroya (somapacitan-beco) is a prescription drug approved to treat growth hormone deficiency. Sogroya comes as a solution inside pre-filled pens and is given as an injection under the skin. Your ...
PLAINSBORO, N.J., Feb. 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya ® ...
New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short Stature (ISS), born Small for Gestational Age (SGA), or Noonan Syndrome (NS) 1 Sogroya ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results